Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-08-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：利润分配管理制度
Governance Information Classification · 95% confidence The document is titled '利润分配管理制度' which translates to 'Profit Distribution Management System' and details the company's policies, procedures, and rules regarding profit distribution, dividend policy, and shareholder returns. It includes chapters on general principles, profit distribution order, policy, supervision, execution, and disclosure. There are no financial statements, audit opinions, or earnings data presented. The document is a policy or governance document outlining internal rules and procedures related to profit distribution and dividends. It is not an announcement, report, or regulatory filing of financial results or voting outcomes. Given the content focuses on internal governance and policy, the most appropriate classification is Governance Information (CGR). The document length is 3251 characters, which is relatively short but contains substantive policy text, not just an announcement or notice.
2025-08-28 Chinese
之江生物：防范控股股东、实际控制人及其他关联方占用资金管理制度
Governance Information Classification · 95% confidence The document is titled as a management system or policy document regarding the prevention of fund occupation by controlling shareholders, actual controllers, and related parties. It outlines principles, measures, responsibilities, and penalties related to fund management and prevention of misuse by related parties. There is no indication that this is a financial report, audit report, earnings release, or any form of regulatory filing announcing financial results or changes. It is a governance-related internal policy document focused on corporate governance and internal control measures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3528 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification, so it is not RPA or RNS.
2025-08-28 Chinese
之江生物：对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '上海之江生物科技股份有限公司 对外投资管理制度' which translates to 'Shanghai Zhijiang Biotechnology Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the principles, approval authorities, management, financial management, and auditing procedures related to the company's external investments. There is no indication that this is a financial report, earnings release, regulatory filing, or announcement. It is a governance-related document describing internal rules and procedures for investment management. Therefore, it fits best under Governance Information (CGR). The document length is 4201 characters, which is substantive and not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2025-08-28 Chinese
之江生物：关于公司部分募投项目变更的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. regarding changes to the use of proceeds from previously raised funds (募投项目变更). It details the reallocation of funds from an original project to a new project, including amounts, approvals, and regulatory compliance. The text includes references to board and supervisory meetings, shareholder approval requirements, and regulatory filings related to fundraising projects. There are no financial statements or comprehensive financial performance data presented, nor is this a transcript, audit report, or earnings release. The document is a formal announcement about changes in capital use related to fundraising projects, which fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive detail about the capital use change, not merely a notice of report publication or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-08-28 Chinese
之江生物：2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is 3369 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-28 Chinese
之江生物：累积投票制实施细则
Governance Information Classification · 95% confidence The document is titled '累积投票制实施细则' which translates to 'Cumulative Voting System Implementation Rules' for Shanghai Zhijiang Biotechnology Co., Ltd. It details the rules and procedures for cumulative voting in the election of directors, including nomination, voting methods, and principles for director election. The content focuses on governance procedures related to board elections rather than financial results, management changes, or shareholder meeting materials. It is a governance-related document outlining internal rules and procedures for board elections, which fits the definition of Governance Information (CGR). The document is relatively short (2860 characters) and does not contain financial data or voting results, so it is not an AGM Information or Voting Results announcement. Therefore, the best classification is Governance Information (CGR).
2025-08-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.